



IRX Therapeutics Announces New Research Collaboration

New York, NY, March 1, 2011 – IRX Therapeutics, a developer of immune therapies to make cancer treatments better, announced today it has signed a research collaboration agreement with one of the world’s leading research-based pharmaceutical companies.

In this collaboration, tumor specimens from subjects treated with IRX-2 and control subjects will be analyzed by the collaborating company using gene analysis technology in order to characterize the action of IRX-2 immunotherapy at the molecular level. The goal is to assess the potential effects of IRX-2 on the tumor microenvironment.

IRX Therapeutics performed a multi-center Phase 2 clinical trial that enrolled patients with newly diagnosed head & neck squamous cell cancer who received IRX-2 immunotherapy prior to surgery.

“This is a great opportunity for IRX Therapeutics to work with one of the leading developers of cancer therapies to further our understanding of the action of our novel immunomodulator, IRX-2. We are hopeful that these studies will further evidence the potential of IRX-2 to effect an immune based attack on a cancer patient’s tumor,” said John W. Hadden II, President and CEO of IRX Therapeutics.

IRX’s lead product candidate, IRX-2, is designed to broadly restore the immune system. This primary cell-derived biologic seeks to overcome cancer-induced immune suppression and restore anti-tumor response, vital steps in successfully treating cancer. The IRX-2 immunomodulator includes multiple cytokine components that work to activate different arms of the immune system.

About IRX Therapeutics

IRX Therapeutics is developing immune therapies that activate a patient’s immune system to defeat cancer and related diseases. The lead platform technology, IRX-2, is designed to broadly restore the immune system by overcoming cancer-induced immune suppression. The targeted result is a durable anti-tumor response. IRX-2’s safety profile and mechanism of action allows it to be combined with cancer vaccines, targeted cancer therapies, and biologic therapies. The Company believes that its products can play an important role in helping a wide range of treatments improve and extend a patient’s life. IRX Therapeutics’ mission is to make cancer treatments better. For more information on IRX Therapeutics, please visit the Company’s website at www.irxtherapeutics.com.

###

Contact:

Jeffrey Hwang

jhwang@irxtherapeutics.com

212-582-1199